Teckna i Cessatechs optionsprogram
Cessatech A/S is a late-stage clinical company developing evidence-based treatment for children.
The lead asset (CT001) is an analgesic nasal spray for treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and, when it has obtained regulatory approval, also being medically approved for children.
Offer in brief
Exercise period: 25 November – 16 December 2021.
Subscription price: Each warrant of series TO 1 gives the holder the right to subscribe for one (1) new share in Cessatech at a price of DKK 10.00.
Issue volume: There are 2,520,000 outstanding warrants of series TO 1. Upon full exercise of warrants of series TO 1, Cessatech will receive approximately DKK 25.2 million before deduction of transaction related costs.
Last day of trading in warrants: 14 December 2021.
Number of outstanding shares in Cessatech: 3,680,000 shares.
Documents